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Background: Triptolide treatment leads to an improvement in Diabetic Cardiomyopathy (DCM) in streptozotocin-
induced diabetic rat model. DCM is characterized by abnormal cardiac energy metabolism. We hypothesized that
triptolide ameliorated cardiac metabolic abnormalities in DCM. We proposed 31P nuclear magnetic resonance
(31P NMR) spectrometry method for assessing cardiac energy metabolism in vivo and evaluating the effect of
triptolide treatment in DCM rats.
Methods: Six weeks triptolide treatment was conducted on streptozotocin-induced diabetic rats with dose of 100,
200 or 400 μg/kg/day respectively. Sex- and age-matched non-diabetic rats were used as control group. Cardiac
chamber dimension and function were determined with echocardiography. Whole heart preparations were
perfused with Krebs–Henseleit buffer and 31P NMR spectroscopy was performed. Cardiac p38 Mitogen Activating
Protein Kinase (MAPK) was measured using real time PCR and western blot analysis.
Results: In diabetic rats, cardiac mass index was significantly higher, where as cardiac EF was lower than control
group. 31P NMR spectroscopy showed that ATP and pCr concentrations in diabetic groups were also remarkably
lower than control group. Compared to non-treated diabetic rats, triptolide-treated diabetic groups showed
remarkable lower cardiac mass index and higher EF, ATP, pCr concentrations, and P38 MAPK expressions. Best
improvement was seen in group treated with Triptolide with dose 200 μg/kg/day.
Conclusions: 31P NMR spectroscopy enables assessment of cardiac energy metabolism in whole heart preparations.
It detects energy metabolic abnormalities in DCM hearts. Triptolide therapy improves cardiac function and increases
cardiac energy metabolism at least partly through upregulation of MAPK signaling transduction.
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Diabetic cardiomyopathy (DCM) is one of the most
common diabetes-associated complications encountered
in the clinical practice [1]. DCM has been known to im-
pair the function of the cardiac muscle and has been as-
sociated with high morbidity and mortality rate [2–5].
DCM occurred independently of coronary artery disease
and hypertension [2, 6, 7].* Correspondence: yangkanxy@gmail.com
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unless otherwise stated.Numerous studies on DCM, either on animal or mo-
lecular study, have found that myocardial abnormal glu-
cose utilization and the shift toward fatty acid oxidation
are the major pathophysiological alterations that may
lead to diabetes mellitus (DM)-associated myocardial re-
modeling and heart failure [2, 4, 5, 7–11].
In diabetic rat model, we previously demonstrated the
significant improvement on myocardial remodeling fol-
lowing triptolide treatment [12]. The inhibition of in-
flammation process by triptolide was evident [12–14].
However, whether triptolide ameliorates cardiac meta-
bolic abnormalities remains unclear [15]. Results fromhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Protein Kinases (MAPK) may play an important role as
MAPK has been known as an important factor that in-
teracts with mitochondria in the production of ATP
[16]. Evidence from previous study revealed that Tripto-
lide treatment could strongly activate MAPK signal
transduction pathways in cells. These findings can be
really intriguing as one may speculate that Triptolide
treatment may improve cardiac energy metabolism by
upregulating MAPK signal transduction [17]. Therefore,
we sought the alteration of MAPK signaling transduc-
tion in rat model following the induction of DCM and
following triptolide treatment. Recently, nuclear mag-
netic resonance (NMR) spectroscopy has been applied
extensively in biomedical field [18, 19]. As a non-
invasive diagnostic method, NMR spectroscopy has ad-
vantage as it allows determination on dynamic changes
of specific metabolites in intact organs or tissues [20, 21],
such as phosphocreatine (pCr), adenosine triphosphate
(ATP), inorganic phosphate (Pi), and intracellular pH
(pHi) [22–24]. In addition, NMR spectroscopy allows
real-time observations on physiological function and
energy metabolism of certain organ (e.g. heart) in near-
physiological condition [20].
In this study, 31Phosphorus NMR (31P NMR) spectros-
copy was used to evaluate the effect of triptolide treat-
ment on the cardiac energy metabolism in DCM rat
model. To minimize interference [25], we decided to
perform the measurement in vitro.
Methods
Animal model and treatment
The protocols used in this study were approved by the
Committee of Animal Care and Use of Central South
University. Eight weeks old male Sprague–Dawley (SD)
rats (Animal Center of Central South University, China)
were included in the study. Animals were placed in lam-
inar flow cages on a 12 h dark and 12 h light cycle and
were fed with standard chow and tap water ad libitum.
DM was induced by injecting streptozocin (STZ, 70 mg/kg,
dissolved in 0.1 M sodium citrate buffer, pH 4.5; Sigma,
USA) intra-peritoneally after overnight fasting. Random
blood glucose levels were measured at 3 days and 1 week
following the injection using One Touch Sure StepTable 1 General data
Control TP DM
Glucose (mmol/l) 6.7 ± 2.0 5.8 ± 1.5 34.3 ±
BW (g) 462.0 ± 21.5 470.0 ± 21.2 213.3
HW (mg) 1190.3 ± 15.3 1210.2 ± 13.4 756.5
HW/BW (mg/g) 2.37 ± 0.33 2.40 ± 0.31 3.92 ±
BW body weight, HW heart weight, TP,L low-dose triptolide (100 μg/kg/day), TP,M med
*P < 0.05 versus Control; #P <0.05 versus DMglucometer (LifeScan, USA). Tail vein bloods were used
and only rats with blood glucose level > 16.7 mmol/l in
both time points were finally used. All the diabetic animals
were randomized into four groups (n = 12 each): three
diabetic groups treated with triptolide (100, 200, or
400 μg/kg/day respectively) and one diabetic group treated
with vehicle. 12 sex- and age-matched non-diabetic rats
served as control group. In addition, to assess the side
effects of triptolide treatment, 12 sex- and age-matched
non-diabetic SD rats (intraperitoneal injection of sodium
citrate buffer) were treated with triptolide 400 μg/kg/day.
After dissolved in dimethylsulfoxide (DMSO), Triptolide
(Chinese National Institute for the Control of Pharma-
ceutical and Biological Products, China) was administered
via gastric irrigation once daily for 6 weeks. At the end of
this study, cardiac function was assessed and animals were
sacrificed. The hearts were quickly extirpated and sub-
jected to biochemical analysis [12].
Cardiac function measurement
Echocardiography was performed using GE Vivid 7
(General Electric, USA) ultrasound system with a 10-
MHz transducer. Prior to the examination [12, 26], rats
were anesthetized with pentobarbital (50 mg/kg intra-
peritoneally) and fixed in the supine position. LV end-
diastolic dimension (LVEDD) as well as LV end-systolic
dimension (LVESD) were measured on the parasternal
long axis view and were indexed to body weight. LV
ejection fraction (LVEF) was also calculated. All mea-
surements were performed in triplicate by an experi-
enced investigator who was blinded to the study and the
results were expressed as the average of obtained value.
13P NMR spectroscopy
31P NMR spectroscopy was performed in a whole heart
as previously described [27]. Briefly, the heart was per-
fused with modified Krebs–Henseleit buffer (11 mmol/L
glucose, 4.5 mmol/l pyruvate, and 0.5 mmol/l lactate, no
phosphate) at constant flow rate (15 ml/min) and pres-
sure (100 mmHg) [28]. The heart was put into 25 mm
NMR tube and subjected to 400 MHz 9.4 T vertical wide
bore superconducting magnet (BrukerBioSpec 9.4 T
Animal MRI System, Switzerland). The temperature of the
heart was kept at 37 °C during the procedure. PeakDM+ TP, L DM + TP, M DM + TP, H
2.7* 33.3 ± 3.7 31.2 ± 3.3* 33.4 ± 2.9*
± 20.1* 236.5 ± 38.4* 234.6 ± 33.1* 225.7 ± 30.3*
± 12.6* 763.5 ± 14.8* 779.4 ± 15.2* 736.5 ± 14.1*
0.48* 3.40 ± 0.46* 3.10 ± 0.46*# 3.01 ± 0.54*#
ium-dose triptolide (200 μg/kg/day), TP,H high-dose triptolide (400 μg/kg/day).
Table 2 Echocardiographic parameters
Control TP DM DM+ TP, L DM + TP, M DM + TP, H
LVEDD, mm 6.4 ± 0.6 6.5 ± 0.7 5.9 ± 0.5 6.0 ± 0.6 5.6 ± 0.6 5.4 ± 0.8
LVEDD index, um/g 13.8 ± 1.6 13.7 ± 2.1 23.6 ± 3.0* 21.1 ± 1.9* 20.2 ± 1.5*# 19.0 ± 1.8*#
LVESD, mm 3.9 ± 0.4 3.8 ± 0.7 3.7 ± 0.6 3.8 ± 0.8 3.3 ± 0.5 3.2 ± 0.8
LVESD index, um/g 8.4 ± 0.8 8.3 ± 0.7 15.8 ± 1.9* 13.5 ± 1.7* 12.9 ± 1.3*# 12.5 ± 1.6*#
LVEF,% 76.4 ± 8.2 78.2 ± 6.3 66.6 ± 6.5* 72.8 ± 5.5 75.0 ± 5.8# 74.6 ± 6.4#
FS,% 44.7 ± 4.3 43.7 ± 5.1 35.8 ± 3.6* 38.9 ± 4.1 41.3 ± 4.9 42.4 ± 4.6
LVEDD left ventricular end-diastolic dimension, LVESD left ventricular end-systolic dimension, LVEF left ventricular ejection fraction, FS fractional shortening. TP,L
low-dose triptolide (100 μg/kg/day), TP, M medium-dose triptolide (200 μg/kg/day); TP, H high-dose triptolide (400 μg/kg/day). *P < 0.05 versus Control;
#P < 0.05versus DM
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to a line width between 20 and 35Hz. Using a spectrom-
eter (Varian, Palo Alto, CA), consecutive 4 minutes of the
spectra were acquired at 161.92 MHz.
Using a computer program (NMR1, Tripos, St. Louis,
MO), the areas of the spectral peaks were fitted to sum
of Lorentzian and Gaussian line shapes. After adjust-
ment for spectral saturation, absolute 31P concentrations
were calculated by adding Atriptolide 10.6 mmol/l to the
initial h-ATP peak area and calculating ATP and PCr
peak areas relative to this area. pH was estimated from
the chemical shift of the inorganic phosphate (Pi) peak
(δPi) relative to that of the PCr peak.
Solutions and ChemicalsA phosphate-free Tyrode solu-
tion was used in heart NMR which contained 136.3 mM
NaCl, 5.4 mM KCl, 1.0 mM MgCl2, 0.9 mM CaCl2,Fig. 1 Comparison of cardiac gross anatomy and systolic function between10.0 mM glucose, and 5.0 mM HEPES [16, 25]. The solu-
tion was pre-warmed to 40 °C and oxygenated with 100 %
Oxygen. For a Na-free solution, Na + and Ca2+ were re-
placed with N-methyl-Dglucamine on an equimolar basis
as follows: 137.2 mMN-methyl-D-glucamine, 5.4 mM KCl,
1.0 mM MgCl2, 10.0 mM glucose, and 5.0 mM HEPES.
Phosphate-free KH solution contained 118 mM NaCl,
5.9 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 25 mM
NaHCO3, 12 mM glucose, and 0.5 mM Na2EDTA. The
KH solution was oxygenated with 95 % O2-5 % CO2.
Real time polymerase chain reaction
Cardiac RNAs were extracted using TRIzol Reagent
(Invitrogen, CA, USA) according to the company’s
protocol. After first strand cDNA synthesis, SYBR
Green Real Time-PCR was performed using SBYRgroups
Table 3 pHi values and concentrations of ATP and pCr in whole heart preparations treated at varying doses of triptolide
Control TP DM DM+ TP, L DM + TP, M DM + TP, H
pHi 7.26 ± 0.12 7.24 ± 0.14 7.20 ± 0.12* 7.22 ± 0.12 7.24 ± 0.12# 7.23 ± 0.12
ATP (mmol/L) 0.17 ± 0.03 0.18 ± 0.01 0.07 ± 0.01* 0.10 ± 0.02*# 0.13 ± 0.02*# 0.14 ± 0.01*#
pCr (mmol/L) 21.3 ± 1.3 21.5 ± 2.8 13.7 ± 1.3* 16.6 ± 1.7*# 18.8 ± 2.3*# 18.9 ± 2.2*#
TP,L low-dose triptolide (100 μg/kg/day), TP,M medium-dose triptolide (200 μg/kg/day), TP,H high-dose triptolide (400 μg/kg/day). *P < 0.05 versus Control; #P <
0.05 versus DM
Fig. 2 Representative image of 31P NMR spectroscopy
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the primers were p38: Forward Primer 5'-TCCAAGGGC
TACACCAAATC-3', Reverse Primer 5'-TGTTCCAGG
TAAGGGTGAGC-3'; β-actin Forward Primer 5'-GAGA
GGGAAATCGTGCGTGAC-3',Reverse Primer 5'-CATCT
GCTGGAAGGTGGACA-3'. The specificity of each PCR
product was validated by the melting curve analysis. The
expressions of mRNA were determined by constructing
the differences between the cycle thresholds (Ct): ΔCt = Ct
gene of interest − Ct housekeeping gene. The conver-
sion of ΔCt to relative gene expression is fold induction
of 2−ΔCt.
Western blot analysis
Cardiac proteins were extracted using radio immune pre-
cipitation assay buffer. Protein concentration was deter-
mined using BCA Protein Assay Kit (CW0014, Beijing
CoWin Bioscience Co. Ltd., China) according to the man-
ufacturer’s protocol. Denaturated proteins were loaded
into every single well and were separated by SDS-PAGE
gel. Gels were transferred to an Immobilon-P membrane
at 290 mA. The antibodies for phosphop38 MAPK and
b-actin were purchased from Cell Signaling Technology
(Beverly, MA). The expression of these proteins in the
membrane was detected using an enhanced chemilumin-
escence kit (Western Bright, Advansta Co., U.S.A.).
Statistical analysis
All data were expressed as mean ± SD and compared by
one way ANOVA with Tukey’s post-hoc test using SPSS
16.0 (SPSS, Inc, Chicago, IL). The correlation between
variables was calculated using linear regression analysis.
Statistical significance was defined as p < 0.05.
Results
All mice treated with Streptozocin developed hypergly-
cemia. During the whole study, no evidence of ketoaci-
dosis was observed in all diabetic mice. No significant
change of blood pressure was observed in all animals.
Compared to non-diabetic groups, all diabetic groups
showed higher cardiac mass index (all p < 0.05). The in-
creased mass indexes were mainly due to the significantly
smaller body weight of the animals in these groups. Com-
parison of blood glucose level and cardiac mass index be-
tween control group and non-diabetic + Triptolide group
showed no significant differences (Table 1).Cardiac performance
When indexed to the body weight, both LVEDD and
LVESD indexes were significantly higher in diabetic than
in non-diabetic rats. LV systolic function, as evidenced
by LVEF, was significantly higher in groups treated with
Triptolide when compared to non-treated group. More-
over, FS in triptolide-treatment diabetic groups also
showed the upward trend compared with the untreated
diabetic group, but the difference did not reach statis-
tical significance (Table 2). The comparison of cardiac
size and function between groups is displayed on Fig. 1.
31P NMR spectroscopy demonstrated that the values
of pHi, ATP and pCr were significantly lower in the un-
treated diabetic rats as compared to non-diabetic rats
(Table 3). A trend of increasing pHi, ATP, and pCr was
observed following Triptolide treatment. Representative
image of 31P NMR spectroscopy is displayed in Fig. 2.
MAPK Signaling pathway
There was a two-fold decrease in p38 mRNA expression
in diabetic rats when compared with control. p38 mRNA
expression was found significantly higher in diabetic rats
treated with Triptolide. Consistently, on Western blot ana-
lysis, both control and Triptolide-treated groups showed
stronger bands for p38 protein expression than those of
diabetic group (all p < 0.05, Table 4, Fig. 3).
Electron microscope
In diabetic rats, myocardial filaments were not intact.
Mitochondria were disorganized with obvious vacuolar
Table 4 p38 mRNA and protein expression (mean ± SD)
Parameter Group
Control DM DM + TP
VEGF mRNA (2-ΔCt) 0.116 ± 0.08 0.060 ± 0.03* 0.086 ± 0.03*#
PKG-1 protein expression (OD) 0.912 ± 0.18 0.413 ± 0.15* 0.704 ± 0.13*#
ΔCt, Ct gene of interest − Ct beta actin; OD, optical density as indexed to beta actin; DM, Diabetes Mellitus; TP, Triptolide. *P < 0.05 versus Control; #P < 0.05
versus DM
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group, myocardial filaments were relatively more intact
with remarkable lesser vacuolar degeneration of mito-
chondria. In contrast, no evidence of vacuolar degener-
ation of mitochondria was found in control group.
Correlation analysis
The correlation between cardiac mass index and ATP as
well as pCr was examined by linear regression analysis.
Cardiac mass index was negatively correlated with ATP
and pCr (r = −0.75 and r = −0.73 respectively, all p < 0.01,
Fig. 5).
Discussion
Diabetes is the most common endocrine disease encoun-
tered in the clinical practice [29]. DM causes series of
metabolic disorders, such as glucose, lipid and protein
metabolism. Long term diabetes can lead to multi-
system of organ damage [23]. Recent studies have associ-
ated mitochondrial dysfunction and DM [8, 29–31].
Mitochondria have been known asthe sites of energy
metabolism. Mitochondrial dysfunction is one of the
characteristics of DM and has occurred even in the early
stage of the disease [5]. Increasing evidences have
supported that mitochondrial energy metabolism dys-
function played a crucial role in the pathogenesis of DM
[11, 26, 32]. Hence, we performed 31P NMR spectros-
copy in order to evaluate the energy metabolism in
DCM rats. Secondarily, we sought to evaluate if Tripto-
lide could improve myocardial energy metabolism.Fig 3 Relative mRNA and protein expression of cardiac p38 MAPK in differeElectron microscope is the common method used for
evaluating the amount and structure of mitochondria.
Cardiac muscle biopsy allows the measurement of ATP
production [20–22]. However, all of these methods are
invasive and can only be performed in vitro. In daily
clinical setting, such kind of method is often found im-
practical. Therefore, a non invasive and reliable tech-
nique is needed. Japanese researchers found that both
31P NMR detection and cardiac biopsy showed the simi-
lar result of myocardial energy metabolism [27]. This
finding makes phosphorus NMR spectroscopy is more
favorable providing that it is a non-invasive technique
and can be performed in vivo. Since the chemical shift
peak of pCr is stable and is not influenced by internal
environment, it is often used as a standard to determine
the remnant compounds of chemical shift such PME, Pi,
PDE and ATP [22, 24]. Energy metabolism can be
assessed by quantifying area calculation under the peak
of each remnant compound, in which ATP is a direct
energy supplier whereas pCr is energy storage [22, 24, 25].
When muscle contracts, pCr transmits high energy phos-
phate bond to ATP for energy supply, conversely, when
muscle relaxes, the reaction of oxidative phosphorylation
in mitochondrial membrane generates ATP and then the
energy is transferred to pCr for storage [25, 27, 33]. Fur-
thermore, phosphorus spectrum enables to calculate intra-
cellular pH, assesses the degree of anaerobic glycolysis,
and evaluates the efficiency of aerobic metabolism in cells
[8, 34], which become an important indicator for assess-
ment of mitochondrial function [25, 28].nt groups
Fig. 4 Electron microscopic analysis of cardiomyocyte. M, Normal mitochondria; Arrow, Mitochondria with vacuolar degeneration
Liang et al. BMC Cardiovascular Disorders  (2015) 15:42 Page 6 of 8Our previous study has demonstrated that cardiac
systolic function was impaired in diabetic rats and the
cardiac index increased significantly [12]. Consistently,
we observed the hemodynamic improvement following
triptolide treatment. However, the exact mechanism
involved in the hemodynamic improvement remains
speculative. We believe the hemodynamic improvement
following the treatment may be due to the anti-fibrotic
property of Triptolide. Based on our previous findings,
pro-fibrotic action of NF Kappa B in STZ mice wereFig. 5 Linear regression analysis between cardiac mass index and ATP as weffectively suppressed by Triptolide [12]. Moreover, Trip-
tolide treatment led to the inhibition of inflammatory cy-
tokines such as Tumor Necrosis Alpha and Interleukin-1
which eventually attenuated the cardiac inflammation. We
speculate that the Triptolide anti-fibrotic effect may lead
to the improvement in ventricular remodeling and myo-
cardial contraction. This, in turn, will ultimately improve
the hemodynamic status of the failing hearts.
In this current study, we demonstrated that high-energy
phosphate metabolism of the whole heart can be assessedell as pCr
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cardiac energy metabolism. As a non-invasive technique,
NMR can be performed repeatedly as a continuous moni-
toring in clinical practice and therefore is important. In
the setting of DM, it may aid especially in the detection
and diagnosis of early stage DM [28].
Our study further confirmed that cardiac energy me-
tabolism was impaired in DM. Cardiac index significantly
increased while cardiac ATP and pCr concentration re-
markably decreased. Triptolide probably inhibited cardiac
remodeling through the immune and inflammatory sup-
pression [12–14]. However, whether the improvement of
cardiac energy metabolism was achieved via the same
mechanism remains largely unclear. On one hand, it is
possible that the inhibition of cardiac remodeling could
improve left ventricular geometry and systolic function.
This will increase cellular blood and oxygen supply which
eventually improve the process of cardiac energy metabol-
ism [3, 6]. On the other hand, our study revealed that
MAPK signaling pathway may be involved in the process.
MAPK mRNA and protein expression which significantly
increased in Triptolide treated group suggested that Trip-
tolide probably improve cardiac energy metabolism at
least partly through MAPK signaling pathway. MAPK sig-
naling pathway is known as the most important pathway
that interacts with mitochondria in the production of ATP
[16]. Mitochondria have been known as the main factory
for ATP production. Interestingly, through electron micro-
scopic analysis, we observed an increasing number of
mitochondria following Triptolide treatment.
Despite significant improvement of LVEF, fractional
shortening (FS) in triptolide-treatment diabetic groups
only showed the upward trend compared with the un-
treated diabetic group. The difference did not reach stat-
istical significance. This may due to sampling error as FS
value itself is lower than EF value. We believe that by in-
creasing sample size, the difference will reach the statis-
tical significance.
Cardiac index and LVEDD were negatively correlated
with cardiac ATP and pCr concentrations, suggesting
that the cardiomyocyte high-energy phosphate bond de-
creased after cardiac remodeling induced by DM. The
decrease of intra-mitochondrial energy production char-
acterized the process and Triptolide can partially reverse
the process. This further affirmed the potential value of
Triptolide treatment in diabetic cardiomyopathy.
Conclusion
In the present study, we show that the abnormalities of
cardiac energy metabolism in DCM rats could be im-
proved partially by triptolide therapy. The improvement of
cardiac energy metabolism following triptolide is at least
partly through the upregulation of MAPK signaling trans-
duction. 31P NMR spectroscopy enables the assessment ofcardiac high-energy phosphates metabolism and therefore
is able to evaluate the cardiac energy metabolism.
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